@article{article_1033564, title={Assessment of miR-1179 As a Potential Biomarker in Juvenile Myoclonic Epilepsy}, journal={Experimed}, volume={12}, pages={1–5}, year={2022}, DOI={10.26650/experimed.2021.1033564}, author={Süsgün, Seda and Toruntay, Ceyhun and Bayrakoğlu, Alişan and Uslu, Ferda and Yücesan, Emrah}, keywords={Juvenile myoclonic epilepsy, miR-1179, ROC curve, biomarker}, abstract={<p>Objective: Juvenile myoclonic epilepsy (JME) is one of the most common childhood types of epilepsy and comprises 5-10% of all epilepsies. Altered expression levels of microRNAs (miRNAs) have been reported in epilepsy as in many diseases. As is known, miRNAs regulate gene expression post-transcriptionally and have potential as diagnostic biomarkers due to their stability in clinical samples. Herein, this study aimed to evaluate miR-1179 levels of JME patients and assess the potential of miR-1179 as a diagnostic biomarker. </p> <p>Material and Method: Twenty patients and 20 healthy controls were recruited in this study and total RNA was extracted from peripheral blood samples of participants. Quantitative real-time polymerase chain reaction (qRT-PCR) was performed to calculate the relative expression level of miR-1179. Additionally, receiver operating characteristic (ROC) curve was conducted to evaluate the diagnostic value of miR-1179 in JME. </p> <p>Results: Expression levels of miR-1179 were statistically significantly increased in patients with JME compared to healthy controls (p<0.0001). ROC analysis revealed that miR-1179 is a well diagnostic biomarker with an area under the curve (AUC) of 0.89. </p> <p>Conclusion: miR-1179 may be considered a remarkable biomarker in the diagnosis of JME. The interaction between miR-1179 and its target Calmodulin 1 (CALM1) should be reinforced through functional studies. Further research in larger cohorts will help to enlighten the etiopathogenesis of JME. </p>}, number={1}, publisher={Istanbul University}